{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:49:57Z","timestamp":1791326997288,"version":"4.3.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.seizure.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T11:38:20Z","timestamp":1786880300000},"page":"52-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of novel anti-seizure medications on status epilepticus in Dravet syndrome: a multicenter real-world cohort study"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8988-4464","authenticated-orcid":false,"given":"Silvia","family":"Lelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0218-9748","authenticated-orcid":false,"given":"Federica","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-1816","authenticated-orcid":false,"given":"Luca","family":"Bergonzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-4223","authenticated-orcid":false,"given":"Jacopo","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7177-4500","authenticated-orcid":false,"given":"Elisabetta","family":"Cesaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-6221","authenticated-orcid":false,"given":"Maria Luigia","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8278-6953","authenticated-orcid":false,"given":"Michela","family":"Quintiliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0491-4021","authenticated-orcid":false,"given":"Domenica Immacolata","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-6419","authenticated-orcid":false,"given":"Duccio Maria","family":"Cordelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-2691","authenticated-orcid":false,"given":"Carla","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.seizure.2026.08.011_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2026.08.011_bib0002","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/320609","article-title":"De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy","volume":"68","author":"Claes","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.seizure.2026.08.011_bib0003","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.08.011_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure"},{"issue":"Pt A","key":"10.1016\/j.seizure.2026.08.011_bib0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","article-title":"Mortality in Dravet syndrome: a review","volume":"64","author":"Shmuely","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"9242","key":"10.1016\/j.seizure.2026.08.011_bib0006","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"issue":"10216","key":"10.1016\/j.seizure.2026.08.011_bib0007","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2026.08.011_bib0008","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"issue":"21","key":"10.1016\/j.seizure.2026.08.011_bib0009","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2026.08.011_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","article-title":"Dravet syndrome: a review of current management","volume":"107","author":"Wheless","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2026.08.011_bib0011","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"International consensus on diagnosis and management of Dravet syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.08.011_bib0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of Dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.seizure.2026.08.011_bib0013","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus: report of the ILAE Task Force","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2026.08.011_bib0014","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/CON.0000000000001103","article-title":"Management of status epilepticus, refractory status epilepticus, and super-refractory status epilepticus","volume":"28","author":"Trinka","year":"2022","journal-title":"Continuum"},{"issue":"8","key":"10.1016\/j.seizure.2026.08.011_bib0015","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","article-title":"Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome","volume":"135","author":"Brunklaus","year":"2012","journal-title":"Brain"},{"issue":"suppl 2","key":"10.1016\/j.seizure.2026.08.011_bib0016","first-page":"S9","article-title":"Clinical course and long-term outcomes in Dravet syndrome","volume":"57","author":"Connolly","year":"2016","journal-title":"Epilepsia"},{"issue":"16","key":"10.1016\/j.seizure.2026.08.011_bib0017","doi-asserted-by":"crossref","first-page":"e1712","DOI":"10.1212\/WNL.0000000000207080","article-title":"Rates of status epilepticus and sudden unexplained death in epilepsy in people with genetic developmental and epileptic encephalopathies","volume":"100","author":"Donnan","year":"2023","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.seizure.2026.08.011_bib0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.seizure.2010.01.007","article-title":"Unusual consequences of status epilepticus in Dravet syndrome","volume":"19","author":"Chipaux","year":"2010","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2026.08.011_bib0019","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1528-1167.2011.03053.x","article-title":"Retrospective multi-institutional study of the prevalence of early death in Dravet syndrome","volume":"52","author":"Sakauchi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.08.011_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","article-title":"Mortality in Dravet syndrome","volume":"128","author":"Cooper","year":"2016","journal-title":"Epilepsy Res"},{"issue":"11","key":"10.1016\/j.seizure.2026.08.011_bib0021","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/brainsci10110889","article-title":"Fatal status epilepticus in Dravet syndrome","volume":"10","author":"De Liso","year":"2020","journal-title":"Brain Sci"},{"issue":"suppl 3","key":"10.1016\/j.seizure.2026.08.011_bib0022","first-page":"S39","article-title":"Dravet syndrome: treatment options and management of prolonged seizures","volume":"60","author":"Cross","year":"2019","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2026.08.011_bib0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0040-1701694","article-title":"Changing landscape of Dravet syndrome management: an Overview","volume":"51","author":"Samanta","year":"2020","journal-title":"Neuropediatrics"},{"issue":"10","key":"10.1016\/j.seizure.2026.08.011_bib0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.braindev.2008.03.002","article-title":"Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)\u2013a nationwide questionnaire survey in Japan","volume":"30","author":"Tanabe","year":"2008","journal-title":"Brain Dev"},{"issue":"5","key":"10.1016\/j.seizure.2026.08.011_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.braindev.2022.01.004","article-title":"The effectiveness of intravenous benzodiazepine for status epilepticus in Dravet syndrome","volume":"44","author":"Kikuchi","year":"2022","journal-title":"Brain Dev"},{"issue":"10","key":"10.1016\/j.seizure.2026.08.011_bib0026","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/epi.18101","article-title":"Pharmacological management of prolonged seizures in Dravet syndrome including intravenous phenytoin","volume":"65","author":"Abi Tayeh","year":"2024","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2026.08.011_bib0027","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","article-title":"Pharmacotherapy for Dravet syndrome","volume":"18","author":"Wallace","year":"2016","journal-title":"Pediatr Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2026.08.011_bib0028","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/epi4.12923","article-title":"Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: a network meta-analysis","volume":"9","author":"Guerrini","year":"2024","journal-title":"Epilepsia Open"},{"issue":"12","key":"10.1016\/j.seizure.2026.08.011_bib0029","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dmcn.15638","article-title":"Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus","volume":"65","author":"Chiron","year":"2023","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2026.08.011_bib0030","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/epi4.13036","article-title":"Efficacy and safety of stiripentol in the prevention and cessation of status epilepticus: a systematic review","volume":"9","author":"Specchio","year":"2024","journal-title":"Epilepsia Open"},{"issue":"10","key":"10.1016\/j.seizure.2026.08.011_bib0031","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1111\/epi.17034","article-title":"Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2026.08.011_bib0032","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/epi.18241","article-title":"Fenfluramine treatment for Dravet syndrome: long term real-world analysis demonstrates safety and reduced health care burden","volume":"66","author":"Boncristiano","year":"2025","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126002396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:03Z","timestamp":1791323403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126002396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"alternative-id":["S1059131126002396"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.08.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of novel anti-seizure medications on status epilepticus in Dravet syndrome: a multicenter real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}